Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study
This study confirms the rapid 3-month effectiveness of IXE on joint disease activity-as fast as TNFi and JAKi (cDAPSA), and exceeding IL-12/23i and IL-23i-along with clear benefits to skin.
Authors
- Àngels Martínez Ferrer
- William Tillett (ORCID: https://orcid.org/0000-0001-7531-4125)
- Khai Jing Ng (ORCID: https://orcid.org/0000-0003-1486-6270)
- Jacques Morel (ORCID: https://orcid.org/0000-0001-7545-6385)
- Dennis McGonagle (ORCID: https://orcid.org/0000-0001-7428-0146)
- Marcus Ngantcha
- Thorsten Holzkämper
- Nicola Gullick (ORCID: https://orcid.org/0000-0001-8970-4116)
- Inmaculada de la Torre (ORCID: https://orcid.org/0000-0002-0037-6134)
- Andris Kronbergs
- Baojin Zhu (ORCID: https://orcid.org/0000-0003-4462-1856)
- Rieke Alten (ORCID: https://orcid.org/0000-0002-3395-4412)
- Vinod Chandran (ORCID: https://orcid.org/0000-0002-8297-0275)
- D. Glenn Kennedy (ORCID: https://orcid.org/0000-0003-3107-6692)
- Walid Fakhouri
- Lars Erik Kristensen
- Ennio Lubrano
Institutions
- University of Molise (IT)
- University of Leeds (GB)
- University Health Network (CA)
- Eli Lilly (United States) (US)
- Université de Montpellier (FR)
- Bispebjerg Hospital (DK)
- University Hospitals Coventry and Warwickshire NHS Trust (GB)
- University of Warwick (GB)
- Centre Hospitalier Universitaire de Montpellier (FR)
- NIHR Leeds Musculoskeletal Biomedical Research Unit (GB)
- Hospital Universitario Doctor Peset (ES)
- Schlosspark-Klinik (DE)
- Montpellier Business School (FR)
- University of Bath (GB)
Publication Details
- Journal
- RMD Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1136/rmdopen-2024-004318
- Citations
- 4
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.96
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Biogen
- Mylan
- Celltrion
- Medac